Each quarter, Locust Walk’s deal team compiles key statistics and trends on strategic transactions and financings. Our 2026 Q2 Report applies the latest data to analyze the current landscape in life sciences deals.
Japan is one of the world’s largest pharmaceutical markets—generally regarded as the second-largest globally. Like their US counterparts, Japanese pharmaceutical companies continue to face significant pipeline replenishment needs as global patent cliffs, pricing pressure, and internal R&D productivity challenges intensify.
Locust Walk examined the evolving landscape of cross-border transactions involving Chinese biotech and what it truly takes to succeed as a global dealmaker in today’s market.
Each quarter, Locust Walk’s deal team compiles key statistics and trends on strategic transactions and financings. Our 2026 Q1 Report applies the latest data to analyze the current landscape in life sciences deals.
Locust Walk conducted a multi‑year analysis of JPM‑week deal activity to evaluate whether early‑January partnering and M&A activity can reliably benchmark and anticipate full‑year dealmaking momentum across global biopharma.
Each quarter, Locust Walk’s deal team compiles key statistics and trends on strategic transactions and financings. Our 2025 Year-In-Review Report applies the latest data to analyze the current landscape in life sciences deals.
Each quarter, Locust Walk’s deal team compiles key statistics and trends on strategic transactions and financings. Our 2025 Q3 Report applies the latest data to analyze the current landscape in life sciences deals.
Each quarter, Locust Walk’s deal team compiles key statistics and trends on strategic transactions and financings. Our 2025 Q2 Report applies the latest data to analyze the current landscape in life sciences deals.
Each quarter, Locust Walk’s deal team compiles key statistics and trends on strategic transactions and financings. Our 2025 Q1 Report applies the latest data to analyze the current landscape in life sciences deals.
Locust Walk analyzed the evolving landscape of China’s biotech out-licensing market and its impact on global dealmaking.